Post‐authorisation safety study to assess the risk of urinary tract cancer in people with type 2 diabetes initiating empagliflozin: A multi‐country European study
No increased risk of UTC, bladder, and renal cancer was observed when empagliflozin initiators were compared with DPP-4i initiators in this non-interventional cohort study.
Authors
- Xu Qiao (ORCID: https://orcid.org/0000-0003-2724-9909)
- Ayman Alhamdow (ORCID: https://orcid.org/0000-0002-3643-0518)
- Laura Saarelainen (ORCID: https://orcid.org/0000-0003-2542-8137)
- Niklas Schmedt (ORCID: https://orcid.org/0000-0002-6226-9537)
- Muriel Lobier (ORCID: https://orcid.org/0000-0003-1174-1288)
- Fabian Hoti (ORCID: https://orcid.org/0000-0002-7464-3549)
- Giorgi Tskhvarashvili (ORCID: https://orcid.org/0000-0002-6616-7503)
Institutions
- Boehringer Ingelheim (Germany) (DE)
- IQM (Finland) (FI)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-06-13
- DOI
- https://doi.org/10.1111/dom.16477
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00